Triheptanoin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Triheptanoin" in English language version.

refsWebsite

Global rank English rank

68^th place

117^th place

447^th place

338^th place

low place

low place

4^th place

4^th place

1globenewswire.com

2,614^th place

1,549^th place

102^nd place

76^th place

europa.eu

ema.europa.eu

"EU/3/12/1081". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 June 2020.
"EU/3/12/1082". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 June 2020.
"EU/3/15/1495". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 June 2020.
"EU/3/15/1508". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 June 2020.
"EU/3/15/1524". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 June 2020.
"EU/3/15/1525". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 June 2020.
"EU/3/15/1526". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 June 2020.
"EU/3/16/1710". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 June 2020.

fda.gov

accessdata.fda.gov

"Dojolvi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 30 June 2020.
"Triheptanoin Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 26 May 2006. Retrieved 30 June 2020.
"Triheptanoin Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 1 February 2008. Retrieved 30 June 2020.
"Triheptanoin Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 21 October 2014. Retrieved 30 June 2020.
"Triheptanoin Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 15 April 2015. Retrieved 30 June 2020.

fda.gov

"Drug Trials Snapshots: Dojolvi". U.S. Food and Drug Administration. 30 June 2020. Retrieved 16 July 2020.

globenewswire.com

"Ultragenyx Announces U.S. FDA Approval of Dojolvi (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders" (Press release). Ultragenyx Pharmaceutical. 30 June 2020. Retrieved 30 June 2020 – via GlobeNewswire.

handle.net

hdl.handle.net

World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3): 694. hdl:10665/330879. License: CC BY-NC-SA 3.0 IGO.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Dojolvi". Health Canada. 23 October 2014. Retrieved 29 May 2022.

nih.gov

dailymed.nlm.nih.gov

"Dojolvi- triheptanoin liquid". DailyMed. 30 June 2020. Retrieved 24 September 2020.